



Quantification Standards for 5' Nuclease Gene Expression Assays



Manohar Furtado Ph.D.
Applied Biosystems

NIST Workshop on Universal RNA Standards
March 28-29 2003

5' Nuclease Assay



1. Real time (Kinetic) PCR assay.

Closed tube format

Can be multiplexed


2. Contamination control is possible.

3. High degree of specificity from two primers and a probe.

4. Good sensitivity and broad dynamic range possible.


5. High efficiency (near 100%) associated with good design. Useful for HT relative quantification.

5' Nuclease Assay



1. Reference for Expression Testing
2. Standards for Quantification.
3. Requirements for assay specificity.

Expression Testing in Tissue Pools



Stratagene Universal Reference RNA (URR) Pool

Adenocarcinoma (mammary gland), Hepatoblastoma (liver), Adenocarcinoma (cervix), Embryonic carcinoma (testis), Glioblastoma (brain), Melanoma, Liposarcoma, Histiocytic lymphoma (macrophage), Lymphoblastic leukemia, (T-cell), Plasmacytoma (B –cell)

Pool 1: testis, liver, kidney RNA (Clontech)

Pool 4: brain, lung & placenta RNA (Clontech)

Testing Gene Expression Assays-on-Demand™ Products

Assays for Human, Mouse & Rat genes


Human Gene Expression assays Ct < 35

First 2500 assays	URR pool	92%
	Pool 1	88%
	Pool 4	93%
	Combined	98%

Total of ~ 20,000 assays: URR pool ~ 70%
30% Tested with pool 1 & 4 ~ 23%

Assays-by-DesignSM Service: Any species / any target

Quantification Standards



Analytical quantification **reference standards** are a known / measured amount of target nucleic acid used to verify that the analytical process is functioning as expected. (e.g. WHO standards for HIV, HCV & HBV).

Quantification standards (QS) may also be used as internal or external **quantitative calibrators** in an assay. The signal from the calibrator is compared against signals from target for purposes of determining the amount of target. (from the manufacturer)

Based on NCCLS Guidelines

Quantification Standards

Non synthetic standards

Bacteria or virus grown in culture and titered

Cellular RNA (reference RNA pools)

DNA from well characterized cell lines.

(Quantified by culture, EM , biochemical methods).

Synthetic standards

Synthetic RNA and DNA templates.

DNA cloned in plasmids.


RNA generated by *in vitro* transcription.

Recombinant retrovirus with target sequence.

Recombinant phage with target sequence.

The phage and viral based standards can be spiked into the sample at the sample preparation stage and carried through the entire process.

Retrovirus Based Standards: HIV ViroSeq™ Kit



1. MICs and mutant virus with drug resistance mutations.
2. Sequenced 420 codons.
3. Reported 75 mutations on an Anti-retroviral Drug Resistance report.
4. Validated 32 mutations for detection at specific WT : Mutant ratios.
5. Each **validated** codon treated as an analyte.
6. Need for an Interpretive algorithm and specification of contraindicated drugs.

Absolute Quantification: IQC Method

A quantitative calibrator is amplified along with target sequence in the same tube.

The IQC may be:

- The same size as the target and distinguished by altered probe binding sites.

- Contain a small insertion or deletion or a restriction enzyme cleavage site that helps differential detection.

Allows detection of inhibitors.


Amplification efficiency of the target and IQC should be similar.

Reportable dynamic range within which the calibrator does not compete with the target should be defined.

Co-amplification of a Competing IQC Target Identical in Size to the Target

Efficiency Tar Amp ~ 100 %

Efficiency IQC Amp ~ 100%



Introduction of 200- 500 copies/ml of IQC does not inhibit target amplification in the 50 to 5×10^6 copies/mL range. Needs extensive optimization


Co amplifying targets the same size as the Target amplicon.

1. **Furtado M R**; Murphy R; Wolinsky S M. Quantification HIV-1 tat mRNA as a marker for assessing the efficacy of antiretroviral therapy. *Journal of Infectious Diseases*. 167(1): 213-6, **1999**.
2. **Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S.** Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. *J Clin Microbiol*. 1994;32:292-300. BASIS FOR THE ROCHE AMPLICOR ASSAY

Co amplifying targets smaller in size compared to the Target amplicon as IQCs

3. **Furtado, MR,** DS Callaway, JP Phair, KJ Kunstman, JL Stanton, CA Macken, AS Perelson and SM Wolinsky. Persistence of HIV-1 Transcription in Peripheral Blood Mononuclear Cells of Patients Receiving Potent Antiretroviral Therapy [see editorial review p1672]. *New England Journal of Medicine*. 340(21): 1614-1622, **1999**.
4. **Wang AM, Doyle MV, Mark DF.** Quantitation of mRNA by the polymerase chain reaction. *Proc Natl Acad Sci U S A*. 1989;86:9717-21 . CYTOKINES

Absolute Quantification: Standard Curve Method




Requires the generation of a standard curve using known amounts of nucleic acid (analyte). Usually done by diluting a **quantitative standard (external calibrator)**.

The external calibrator is not in the same well as the target.

Calibrators do not compete with the target. Targets identical in sequence can be used.

Assay conditions may vary from well to well. Minimal with newer instruments.

Use of Standard Curves



Wang and Morris Anal. Biochem. 269:198-201 (1999)

Quantification Relative to an Endogenous Control

Cellular transcripts whose levels do not change during the course of the experiment can serve as endogenous controls / reference.

18S RNA

ADA

β -actin

GAPDH

Rb

EF-1 α

UbcH5B

MLN51

Warrington et al., *Physiol. Genomics*, **2**:143-147 (2000)

Hamalainen et al., *Anal Biochem.* **299**:63-70 (2001)

Is there an endogenous control ?

User defined from experience with the system.

Needs validation.

Multiple controls.

Spike in a constant amount of an **exogenous standard RNA** to serve as an quantification standard into all samples.

Normalize data across all samples and identify an endogenous control that changes minimally across the study.

Relative Quantification

1. Using efficiency values in the PCR equation

$$\frac{(1+E_{\text{ref}})^{\{Ct_{\text{ref}2} - Ct_{\text{ref}1}\}}}{(1+E_{\text{tar}})^{\{Ct_{\text{sam}1} - Ct_{\text{sam}2}\}}} = \text{Fold Change}$$

Liu and Saint, *Anal. Biochem.* **302**:52-59; 2002

Efficiency values derived for target gene and reference can be used with the Ct values obtained to calculate fold change.


Accurate determination of assay efficiency is difficult. Requires the use of a broad dynamic range (5 to 6-logs) of target dilution and multiple determinations.

2. Using the delta delta Ct method Heid et al *Genom Res*, 6:986-994; 1996.

If $E_{\text{ref}} = E_{\text{tar}} = 1$ the above equation will change to $2^{-\Delta\Delta Ct}$

Most useful for higher throughput. No need for efficiency values.

Measuring Efficiency Values



Range 2- log

82-112

97.6 Avg

N= 76

Range 5- log


92-105

98.4 Avg

N= 22


Effect of Ct Measurement Variations on Efficiency Results

Log fold Dilution	Ct Variation	Measured Efficiency Range
1.0	1.0	70 to 168%
2.0	1.0	82-125%
3.0	1.0	87-115%
4.0	1.0	89-110%
5.0	1.0	92-108%



$$\text{Efficiency} = 10^{(-1/\text{slope})} - 1$$

Dynamic Range and Sensitivity




Sensitivity Range estimate of 50 to 250 copies

Dynamic Range: 6-logs

03/28/03

NIST Workshop

Assay Efficiency: Total 508



Efficiency Range: 90-109% ($100 \pm 10\%$)


Over 700 assays tested.

Amplicon size range 56 -186.

No correlation to GC content.


No correlation to secondary structure.

Relative Quantification NHT @ 94%



GAPDH @ 97.5%. 3, 10 & 100 fold dilution of total RNA

RQ Experimental Design; Reproducibility



1. Number of Assays Selected	15	
• Low Expressors	26-30 Ct 10,000 to 2000	5
• Moderate Expressors	22-26 Ct 100,000 to 10,000	5
• High Expressors	18-22 Ct 1,000,000 to 100,000	5
2. Dilutions/ Amounts: 100; 50; 30; 10 and 1 ng /well		
3. Number of Operators		3
4. Number of Runs		3
5. Number of sites / instrument		1
6. Number of Replicates		3

RQ: Results Summary

Operator to Operator Variation: 2-Fold Change

	N	Range	AVG	SD	Median	95% CI	< 1.5	Accuracy (1.33)	Accuracy (1.50)
Exp_FC 2 and All OPER	387	0.97 to 6.03	2.23	0.5	2.18	1.23 to 3.23	6 or 1.5%	97.40%	96.80%
Exp_FC 2 and OPER 1	120	1.59 to 4.71	2.29	0.53	2.15	1.23 to 3.35	0	100%	100%
Exp_FC 2 and OPER 2	133	0.97 to 6.03	2.14	0.62	2.03	0.90 to 3.38	6 or 4.5%	92.50%	90.90%
Exp_FC 2 and OPER3	134	1.76 to 3.14	2.29	0.29	2.23	1.71 to 2.87	0	100%	100%

Conclusions : Quantification

1. Internal calibrators or standard curves are necessary for accurate absolute quantification.
2. For relative quantification it is useful to have an endogenous control that is minimally altered during the study / experiment.
3. Quantification standards that can be added into the sample (or during NA extraction) and carried through the entire process are useful for normalization across large studies and identification of appropriate endogenous controls.

Conclusions .. continued

4. Efficiency measurements have a high degree of variability. Using these values in RQ measurements gives less robust results.
5. The $\Delta\Delta C_t$ method produced a better correlation to expected results as compared to measurements using efficiency values in PCR equations.
6. Good assay design strategies can ensure near 100% efficiency for real time PCR assays.
7. Relative quantification using the $\Delta\Delta C_t$ method generated reliable results.

Assay Specificity


Duplicated Loci in the Human Genome

Science 297:1003 Aug 2002

INTERPRO (entry number)	Description	Number		Enrichment*
		Duplicated	Unique	
003006	Immunoglobulin and major histocompatibility complex	38	280	4.0
001400	Somatotropin hormone family	17	1	31.8
001254	Serine proteases, trypsin family	11	75	4.3
001909	KRAB box	10	87	3.5
001128	Cytochrome P450 enzyme	8	41	5.5
002999	Tudor domain	6	21	7.5
001870	Domain in various γ -carboxylases	5	35	4.2
003877	SPla and the ryanodine receptor (SPRY)	5	42	3.6
001664	Intermediate filament proteins	5	42	3.6
000566	Lipocalin-related protein and Bos/Can/Equ allergen	5	21	6.5
000359	Cystine-knot domain	5	17	7.7
001039	Major histocompatibility complex protein, class I	5	9	12.0
001811	Small cytokines, interleukin 8-like	4	40	3.1
000436	Sushi domain/SCR repeat/CCP module	4	39	3.1
001545	Glycoprotein hormone β chain	4	2	22.5
001271	Mammalian defensin	4	2	22.5
000340	Dual-specificity protein phosphatase	3	39	2.4
003575	Small GTPase, Ras subfamily	3	24	3.7
004045	Glutathione S-transferase NH ₂ terminus	3	18	4.8
000863	Sulfotransferase	3	16	5.3
001079	Galectins (previously S-lectins)	3	10	7.8
000971	Globin	3	8	9.2
000461	Glycoside hydrolase family 13	3	3	16.8
000353	Class II histocompatibility antigen, β chain, β_1	3	2	20.2

*Enrichment was calculated as the fraction of duplicated domains for an INTERPRO number over the average fraction for all INTERPRO domains detected in the genome (647 duplicated/21,147 total). Table S7 provides a complete list of all INTERPRO domains examined by this analysis.

Selectivity by Primer Mismatches




B

	Exon 8		Exon 9	
<i>CYP2D6</i>	GCCTTCCTGC	CTTTCTCAGC	AGGCCGCCGT	GCATGCCTCG GGG.AGCCC
<i>CYP2D7P</i>	GCCTTCCTGC	CTTTCTCAGC	AGGCCGCCGT	GCATGCCTCG GGG.AGCCC
<i>CYP2D8P</i>	GCCTTCCTGC	CTTTCTCAGC	AGGCCGCCGT	GCATGCCTCG GGCCAGCCC *
<i>CYP2D6</i>	CTGGCCCGCA	TGGAGCTCTT	CCTCTTCTTC	ACCTCCCTGC TGCAGCACI
<i>CYP2D7P</i>	CTGGCCCGCA	TGGAGCTCTT	CCTCTTCTTC	ACCTCCCTGC TGCAGCACI
<i>CYP2D8P</i>	CTGGCCCGCA	TAGAGCTCTT *	CCTCTTCTTC	ACCTCCCTGC TGCAGCACI
<i>CYP2D6</i>	TCAGCTTCTC	GGTGCCCACT	GGACAGCCCC	GGCCCAGCCA CCATGGTGT
<i>CYP2D7P</i>	TCAGCTTCTC	CGTGGCCGCC	GGACAGCCCC	GGCCCAGCCA CTCTCGTGT
<i>CYP2D8P</i>	TCAGCTTCTC	GGTGCCCACT	GGACAGCCCC	GGCCCAGCCA CTCTCGTGT
		* * * *		* * *
<i>CYP2D6</i>	CTTTGCTTTC	CTGGTGAGCC	CATCCCCCTA	TGAGCTTTGT GCTGTGCCC
<i>CYP2D7P</i>	CGTCAGCTTT	CTGGTGAGCC	CATCCCCCTA	CGAGCTTTGT GCTGTGCCC
<i>CYP2D8P</i>	CGTCGGCTTT	CTGGTGAGCC	CATCCCCCTA	TGAGCTTTGT GCTGTGCCC
	* * * * *	**		*

Anal Biochem. 300:
121-131. 2002
Cytochrome P450
CYP2D6

Effect of a Mismatch



The Ct value is dependent on both amplification & probe cleavage.

Effect of mismatches in primers & probe on Ct.

- Position specific effects.

- Mismatch specific effects.

- Combinatorial effects of multiple mismatches


Relative contributions from primers & probes.

In silico QC against the known transcriptome.

Determining Level of Assay Specificity

Ct diff AT1 vs T = 9

Ct



Mismatches

Probe



For primer



Rev primer

Target T

Related gene AT

Determining Level of Assay Specificity

Ct diff AT1 vs T= 15



Transcript Abundance

Classes	Copies/cell	No. transcript/cell	Abundance
Low	1--15	11,000	< 0.004%
Intermediate	200-400	500	< 0.1%
High	10,000	< 10	3%

Based on Abundance & distribution
of SAGE tags

Gene Expression: Levels of Induction

Expression levels of the majority of genes in a cell are altered by 2 to 10-fold *in vivo*.


Data from IFN regulated genes; Brian Williams; Cleveland Clinic

Fold Change	IFN -a	IFN -b	IFN -g
>1000	None	None	None
100-1000	None	2	None
50-100	1	1	None
25-50	3	3	2
10 to 25	8	4	4
2 to 10	143	178	194
<2-fold	1185	1152	1140
Total	1340	1340	1340

Conclusions

1. Real time PCR assays that target transcripts emanating from closely related genes should have high selectivity.
2. Suppression of co-amplification can be achieved by placing primers at positions where there are mismatches.
3. Mismatches within probe binding regions will also enhance selectivity.
4. The level of selectivity should be defined by the user based on the study / experiment and is related to transcript abundance and levels of induction / suppression of the related genes.

Acknowledgements



Dennis Gilbert
Gene Spier


Karl Guegler

Ken Livak

Olga Petrauskene
Karen Poulter
Rixun Fang
Michael Malicdem
Shashi Amur
Ada Wong
Sonny Young
Eileen Westphale

Kathleen Shelton

Labeling



For Research Use Only. Not for use in diagnostic procedures.

The PCR process and 5' nuclease process are covered by patents owned by Roche Molecular Systems, Inc. and F. Hoffmann-La Roche Ltd.

Applied Biosystems is a registered trademark and AB (Design), Applera, Assays-by-Design, Assays-on-Demand, and ViroSeq are trademarks of Applera Corporation or its subsidiaries in the US and/or certain other countries.

© 2003 Applied Biosystems. All rights reserved.

03/28/03

NIST Workshop

AB Applied
Biosystems